Free tool
FAERS Monitor: Alphagan P
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021770 or its brand name (Alphagan P, Brimonidine Tartrate). Reports on generic versions are filed under their own applications.
Reports
9,475
Serious
4,593
48% of reports
Hospitalization
1,856
Death reported
491
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain602
- eye irritation599
- drug ineffective591
- ocular hyperaemia574
- fatigue464
- vision blurred458
- intraocular pressure increased397
- off label use395
- dizziness374
- headache374
- diarrhoea300
- dyspnoea298
- death282
- visual impairment275
- asthenia264
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 56 |
| 2006 | 55 |
| 2007 | 74 |
| 2008 | 59 |
| 2009 | 126 |
| 2010 | 85 |
| 2011 | 127 |
| 2012 | 232 |
| 2013 | 255 |
| 2014 | 406 |
| 2015 | 654 |
| 2016 | 754 |
| 2017 | 721 |
| 2018 | 638 |
| 2019 | 691 |
| 2020 | 837 |
| 2021 | 547 |
| 2022 | 576 |
| 2023 | 598 |
| 2024 | 619 |
| 2025 | 633 |
| 2026 | 692 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,684 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 397 | 71.1 | 64.5 | 26,548 |
| ocular hyperaemiaSignal | 574 | 27.2 | 25.1 | 14,297 |
| eye painSignal | 602 | 23.9 | 22.1 | 13,098 |
| eye irritationSignal | 599 | 23.3 | 21.6 | 12,684 |
| vision blurredSignal | 458 | 7.4 | 6.8 | 2,548 |
| visual impairmentSignal | 275 | 4.9 | 4.4 | 862 |
| dizziness | 374 | 1.7 | 1.5 | 101 |
| asthenia | 264 | 1.6 | 1.4 | 53 |
| headache | 374 | 1.3 | 1.2 | 30 |
| fatigue | 464 | 1.3 | 1.2 | 38 |
| dyspnoea | 298 | 1.2 | 1.0 | 7 |
| diarrhoea | 300 | 1.0 | 0.9 | 0 |
| off label use | 395 | 1.0 | 0.9 | 0 |
| drug ineffective | 591 | 1.0 | 0.9 | 0 |
| death | 282 | 0.7 | 0.6 | 30 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.